Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects:

Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

The spike-in of synthetic hsa-lest-7a-5p miRNA decreases the Ct Values of extracted small RNA samples. by Marc Van Der Hofstadt (1423027)

Subjects:

General characteristics and clinical data of the subjects included in the study. by Spela Kokelj (8356644)

Subjects:

Variants assigned Clinvar pathogenic clinical significance. by Anastasiia Buianova (19871022)

Subjects:

Introgression decreases allelic shuffling. by Enrique J. Schwarzkopf (6579275)

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

Distribution of significant SNVs across disease severity. by Varsha Ravi (12267659)

Subjects:

The small blue circles show the IC-volume (mean of left and right) from 72 males and the small red squares from 51 females as a function of age. by Pingling Kwok (14896191)

Patterns, classification, and clinical significance of pharmacist interventions. by Osama Mohamed Ibrahim (12006954)

Subjects:

Patients’ demographics and clinical parameters. by Zi-Rong Chen (9227618)

Subjects:

Demographics of the study population. by Sohyun Park (78358)

Subjects:

Table 3 - by Sohyun Park (78358)

Subjects: